Aprepitant for Chemotherapy-Induced Emesis

CMS covers an all‑oral three‑drug antiemetic regimen (aprepitant + oral 5HT3 antagonist + oral dexamethasone) for patients receiving specified anticancer agents or agents designated highly/moderately emetogenic by at least two of NCCN, ASCO, and ESMO/MASCC; coverage lists differ by effective dates (pre‑May 29, 2013 and on/after May 29, 2013). The regimen must be given entirely orally and timed immediately before and within 48 hours after chemotherapy; aprepitant alone or mixed oral/IV antiemetic regimens are not covered under Medicare Part B.

"For services performed between April 4, 2005 and May 28, 2013, the oral three‑drug regimen (oral aprepitant + oral 5HT3 antagonist + oral dexamethasone) is reasonable and necessary for patients rec..."

Sign up to see full coverage criteria, indications, and limitations.